Unicycive Therapeutics Inc

Unicycive Therapeutics: No new developments or financial updates, only current fundamentals remain unchanged.

Unicycive Therapeutics secures FDA approval to review its oxylanthanum carbonate for hyperphosphatemia—boosting hopes for kidney‑disease treatment and investor growth.

Unicycive Therapeutics wins FDA acceptance for its kidney‑disease drug oxylanthanum carbonate, but an investor probe looms—will the approval spark a share rally or trigger caution?

Unicycive Therapeutics faces volatility as it pursues hyperphosphatemia treatments for kidney disease patients, seeking breakthroughs amid financial uncertainty.

Unicycive Therapeutics resubmits NDA for kidney‑disease hyperphosphatemia therapy; analysts eye $46 target as FDA review moves forward.

Unicycive Therapeutics focuses on developing novel hyperphosphatemia treatments for CKD and AKI, aiming to address unmet kidney disease needs and improve patient outcomes.

Unicycive Therapeutics, a biotech company, has received a Complete Response Letter from the FDA regarding its treatment for hyperphosphatemia, but plans to address manufacturing issues and move forward with its New Drug Application.

Unicycive Therapeutics Inc’s stock plummeted 35% after the FDA flagged significant manufacturing deficiencies at a third-party vendor, casting a shadow over the company’s New Drug Application for a promising kidney disease treatment.

Unicycive Therapeutics Inc.’s stock declined 35% after the FDA announced manufacturing deficiencies at a third-party vendor, delaying a key treatment’s approval and raising concerns about the company’s future growth prospects.

Unicycive Therapeutics Inc. saw its stock price drop 35% after the FDA identified manufacturing deficiencies at a third-party vendor, delaying the approval of its key treatment for hyperphosphatemia.